Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Biogen (NASDAQ:BIIB) and maintains a $294 price target.
June 28, 2024 | 9:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Biogen and maintains a $294 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $294 price target by a reputable analyst suggests a positive outlook for Biogen. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100